Живи долго! Научный подход к долгой молодости и здоровью. Майкл Грегер
Читать онлайн книгу.
https://pubmed.ncbi.nlm.nih.gov/32169310/
887
Chi F, Wu R, Zeng Y, Xing R, Liu Y. Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis. Mol Biol Rep. 2013;40(5):3583–90. https://pubmed.ncbi.nlm.nih.gov/23269623/
888
Travis RC, Appleby PN, Martin RM, et al. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res. 2016;76(8):2288–300. https://pubmed.ncbi.nlm.nih.gov/26921328/
889
Cao H, Wang G, Meng L, et al. Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: a meta-analysis. PLoS One. 2012;7(11):e49884. https://pubmed.ncbi.nlm.nih.gov/23185474/
890
Li Y, Li Y, Zhang J, et al. Circulating insulin-like growth factor-1 level and ovarian cancer risk. Cell Physiol Biochem. 2016;38(2):589–97. https://pubmed.ncbi.nlm.nih.gov/26845340/
891
Gong Y, Zhang B, Liao Y, et al. Serum insulin-like growth factor axis and the risk of pancreatic cancer: systematic review and meta-analysis. Nutrients. 2017;9(4):394. https://pubmed.ncbi.nlm.nih.gov/28420208/
892
Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet. 1998;351(9113):1393–6. https://pubmed.ncbi.nlm.nih.gov/9593409/
893
Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst. 2012;104(13):975–81. https://pubmed.ncbi.nlm.nih.gov/22761272/
894
Quan H, Tang H, Fang L, Bi J, Liu Y, Li H. IGF1(CA)19 and IGFBP-3–202A/C gene polymorphism and cancer risk: a meta-analysis. Cell Biochem Biophys. 2014;69(1):169–78. https://pubmed.ncbi.nlm.nih.gov/24310658/
895
Yokoyama NN, Denmon AP, Uchio EM, Jordan M, Mercola D, Zi X. When anti-aging studies meet cancer chemoprevention: can anti-aging agent kill two birds with one blow? Curr Pharmacol Rep. 2015;1(6):420–33. https://pubmed.ncbi.nlm.nih.gov/26756023/
896
Elia I, Doglioni G, Fendt SM. Metabolic hallmarks of metastasis formation. Trends Cell Biol. 2018;28(8):673–84. https://pubmed.ncbi.nlm.nih.gov/29747903/
897
Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev. 2009;30(1):51–74. https://pubmed.ncbi.nlm.nih.gov/19075184/
898
Yang SY, Miah A, Pabari A, Winslet M. Growth factors and their receptors in cancer metastases. Front Biosci (Landmark Ed). 2011;16:531–8. https://pubmed.ncbi.nlm.nih.gov/21196186/
899
Zhang Y, Ma B, Fan Q. Mechanisms of breast cancer bone metastasis. Cancer Lett. 2010;292(1):1–7. https://pubmed.ncbi.nlm.nih.gov/20006425/
900
Yang SY, Miah A, Pabari A, Winslet M. Growth factors and their receptors in cancer metastases. Front Biosci (Landmark Ed). 2011;16:531–8. https://pubmed.ncbi.nlm.nih.gov/21196186/
901
Sohn K. Now, the taller die earlier: the curse of cancer. J Gerontol A Biol Sci Med Sci. 2016;71(6):713–19. https://pubmed.ncbi.nlm.nih.gov/25991828/
902
Salvioli S, Capri M, Bucci L, et al. Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53. Cancer Immunol Immunother. 2009;58(12):1909–17. https://pubmed.ncbi.nlm.nih.gov/19139887/
903
Piantanelli L. Cancer and aging: from the kinetics of biological parameters to the kinetics of cancer incidence and mortality. Ann N Y Acad Sci. 1988;521:99–109. https://pubmed.ncbi.nlm.nih.gov/3377369/
904
Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005;120(4):449–60. https://pubmed.ncbi.nlm.nih.gov/15734678/
905
Stanta G, Campagner L, Cavallieri F, Giarelli L. Cancer of the oldest old. What we have learned from autopsy studies. Clin Geriatr Med. 1997;13(1):55–68. https://pubmed.ncbi.nlm.nih.gov/8995100/
906
Salvioli S, Capri M, Bucci L, et al. Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53. Cancer Immunol Immunother. 2009;58(12):1909–17. https://pubmed.ncbi.nlm.nih.gov/19139887/
907
Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone: a new inborn error of metabolism? Isr J Med Sci 1966;2:152–5. https://pubmed.ncbi.nlm.nih.gov/5916640/
908
Guevara-Aguirre J, Bautista C, Torres C, et al. Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador. Rev Endocr Metab Disord. 2021;22(1):59–70. https://pubmed.ncbi.nlm.nih.gov/33047268/
909
Laron Z, Kauli R, Lapkina L, Werner H. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome. Mutat Res Rev Mutat Res. 2017;772:123–33. https://pubmed.ncbi.nlm.nih.gov/28528685/
910
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13. https://pubmed.ncbi.nlm.nih.gov/21325617/
911
Boguszewski CL, Boguszewski MC da S. Growth hormone’s links to cancer. Endocr Rev. 2019;40(2):558–74. https://pubmed.ncbi.nlm.nih.gov/30500870/
912
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13. https://pubmed.ncbi.nlm.nih.gov/21325617/
913
Laron Z, Kauli R, Lapkina L, Werner H. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome. Mutat Res Rev Mutat Res. 2017;772:123–33. https://pubmed.ncbi.nlm.nih.gov/28528685/
914
Ma H, Zhang T, Shen H, Cao H, Du J. The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy. Br J Clin Pharmacol. 2014;77(6):917–28. https://pubmed.ncbi.nlm.nih.gov/24033707/
915
Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15(1):80–101. https://pubmed.ncbi.nlm.nih.gov/8156941/
916
Lee C, Safdie